Actemra Arthritis Drug Lawsuit

Colored X-ray of the hands of a patient with rheumatoid arthritis. Image credit: Zephyr/Science Source.

Hundreds of patients have died while taking ACTEMRA® for rheumatoid arthritis

The attorneys at Heninger Garrison Davis are currently investigating claims that patients taking the arthritis drug, ACTEMRA®, by injection or IV, may have suffered serious health problems including death.

A recent analysis of over 500,000 side-effect reports on rheumatoid arthritis medicines revealed that Actemra® (tocilizumab) is linked to many devastating side effects — all of which the manufacturer failed to warn doctors and patients of, including…

  • Heart attack
  • Heart failure
  • Stroke
  • Pancreatitis
  • Interstitial lung disease
  • Gastrointestinal perforation (tears)
  • And even, death

Study Reveals ACTEMRA® Patients Experience Unusually Large Number of Serious Side Effects Not Listed On Drug’s Warning Label

A study conducted by STAT® researchers analyzed 13,500 reports of adverse medication events submitted to the FDA since 2010.

The goal was to discover if there was a medication currently on the market that had an alarmingly high rate of serious side effects not already associated with the medication.

It found one…

The medical community, as well as the 760,000 patients using Actemra®, were shell-shocked to read the study’s conclusion, which stated…

“Actemra® stood out.”

“Actemra® patients had experienced an unusually large number of serious side effects that didn’t appear on the drug’s warning label.”

Watch this extremely important video to understand what this study’s findings were and what it means for you…

About Actemra® :: Did You (or Someone You Know) Take This Medication?

Actemra® (also known as tocilizumab) is a popular medicine prescribed for the following conditions:

  • Rheumatoid Arthritis (RA)
  • Giant Cell Arteritis (GCA)
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Systemic Juvenile Idiopathic Arthritis (SJIA)
  • …and 60+ other “off-label” conditions

Actemra® is delivered through injection (ie. at home) or through intravenous infusion (IV).

Actemra® (also known as tocilizumab) was first approved by the FDA in January, 2010.

Since then, more than 760,000 patients have been prescribed Actemra® globally.

The drug’s manufacturer, Roche®, brought in $1.7 billion in gross sales of Actemra® in 2016 alone.

The drug is the pharmaceutical’s fifth highest in gross sales.

How To Pursue Financial Compensation If You (Or A Loved One) Was Affected…

Our legal team has reviewed the available evidence and our experience tells us that we are in position to effectively represent victims who have suffered health and unintended financial consequences due to the Actemra® medication.

We are currently investigating and accepting cases from all 50 states.

Get A Free Legal Consultation With Our Actemra® Attorneys

Even if you feel you are not ready to file a suit, consult one of our qualified lawyers as soon as possible so that you will know your options. We do not charge any fees upfront. In fact, we will only charge attorney’s fees if we obtain a financial settlement for you. If you don’t win, we won’t get paid a legal fee. Call us today for your free case evaluation 1.800.241.9779.

Click Here to Contact Us

Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients

Important Facts Regarding Actemra®

Additional data from the STAT® research study suggested Actemra® users were 50% more likely to have a heart attack or stroke than patients taking alternative rheumatoid arthritis (RA) drug, Enbrel®.

The alternative drug, Enbrel®, DOES include heart attack and stroke in its warning label — BUT ACTEMRA® DOES NOT WARN OF THESE RISKS.

Roche® (with its subsidiary, Genentech®) who is the manufacturer of Actemra® may have failed to warn doctors and patients of these serious side effects.

Instead… the manufacturer has widely marketed Actemra® as being an option that does NOT carry these side effects — which many in the medical community believe is a serious error.

Analysis of FAERS (FDA’s Adverse Event Reporting System) data showed 1,128 people died after taking Actemra®.

The STAT® report even mentioned some particularly frightening findings….

“In one striking example, obtained through the Freedom of Information Act, a doctor said no factor other than the drug could have explained a 73-year-old man’s fatal brain bleed two days after receiving an intravenous Actemra® treatment.”

Many in the medical community estimate FAERS data only represents approximately 10% of the total adverse events that actually occursince most adverse events in patients go unreported to the FDA.

This suggests that perhaps tens of thousands of people have died after taking Actemra®…

…And potentially hundreds of thousands have suffered serious side effects while taking Actemra®.

In a head-to-head comparison, the STAT® study demonstrated that users of Actemra® had a higher incidence of interstitial lung disease versus the popular alternative rheumatoid arthritis (RA) drug, Remicade®.

Interstitial lung disease is the scarring of lung tissue which affects a person’s ability to breathe and deliver oxygen into the bloodstream.

Sadly, it is generally considered an irreversible condition.

Though considered an extremely rare (and deadly) condition, the STAT® study found a whopping 132 patients developed Pancreatitis while taking Actemra®.

26 of the 132 Actemra® patients with pancreatitis died.

Dr. David Felson, a Boston University rheumatologist who was present at the initial FDA Advisory meetings shared his concerns over the recent STAT® study…

“Pancreatitis is very, very rare… So if I see a signal for pancreatitis among [Actemra®] users, I would be worried.”

Why Weren’t Doctors & Patients Properly Warned?

But why did it take the STAT® organization to uncover this?

Why didn’t Roche® (the drug’s manufacturer), bring to light these mounting adverse event reports at the FDA and subsequently add these health risks to the drug’s warning label?

Many in the medical community are now urging that the FDA mandate Roche® to label Actemra® with warnings for…

  • Heart attack
  • Heart failure
  • Stroke
  • Pancreatitis
  • Interstitial lung disease
  • Gastrointestinal perforation (tears)
  • And even, death

It’s important, as a patient, to understand that there are strict rules that pharmaceutical companies must adhere to (as mandated by the FDA), that ensure doctors and their patients are properly informed of the risks associated with any drug.

Drug companies are forced, by law, to disclose all known health risks associated with their drug.

They disclose these risks on the drug’s “label”, in the form of a warning.

Despite the FDA’s Adverse Event Reporting data and the STAT® report, Roche® (and its subsidiary, Genentech®) may have failed to properly warn the medical community of the known risks of heart attack, heart failure, stroke, pancreatitis, lung disease and GI perforation with Actemra®.

You (the patient), and your doctor, deserved the opportunity to make an informed decision about the safe use of Actemra® — weighing all the known risks against the benefits it might provide.

As a result of the manufacturer of Actemra® failing to properly warn patients and doctors of these serious risks, you or your loved one likely suffered significant health problems, emotional and physical stress, as well as unintended financial burdens — like doctor or hospital visits, time off work, necessary treatments and/or therapies to recover.

As a victim of a drug that may have failed to properly warn you of potentially life threatening conditions, you may be entitled to what are called “money damages“, which is a legal term for financial compensation awarded from individual lawsuits, settlements or class action lawsuits.

All potential Actemra® lawsuits are currently being investigated on the grounds that Roche® (maker of Actemra®)

  • failed to properly warn patients and doctors of many known and serious risks
  • failed to conduct adequate pre-market clinical trials
  • Fraudulently sold and marketed their product despite knowledge of the drug’s undisclosed risks